1984 Volume 32 Issue Supplement9 Pages 291-299
AC-1370 was clinically evaluated. The results obtained were summarized as follows:
1) Antibacterial activity of AC-1370 against clinical isolates of P. aeruginosa was superior to that of CFX, CTM and CZX, although its activity against E. coli was inferior to that of CFX, CTM and CZX.
2) The activity against K. pneumoniae, S. marcescens, P. cepacia and A. calcoaceticus was almost same as that of CFX and CTM.
3) AC-1370 was given to 13 patients: 8 respiratory infection cases, 2 cholecytistis cases, 2 sepsis cases and 1 urinary tract infection case. Clinical response to AC-1370 treatment was excellent in 4 cases, good in 4 cases, fair in 1 case and poor in 4 cases with effective rate of 61.5% (8 case of 13 cases).
4) Bacteriological response in the above 13 cases was eradicated in 1 case, persisted in 1 case and colonization in 3 cases, and the remaining 8 cases were unevaluable.
5) Neither side effect nor abnormality in laboratory findings was observed.
6) The drug is expected to be a useful antibiotic, if an adequate selection of patients is considered.
